221 related articles for article (PubMed ID: 27911106)
21. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
[TBL] [Abstract][Full Text] [Related]
22. Ripasudil: first global approval.
Garnock-Jones KP
Drugs; 2014 Dec; 74(18):2211-5. PubMed ID: 25414122
[TBL] [Abstract][Full Text] [Related]
23. Time Course of Prostaglandin Analog-related Conjunctival Hyperemia and the Effect of a Nonsteroidal Anti-inflammatory Ophthalmic Solution.
Sakata R; Sakisaka T; Matsuo H; Miyata K; Aihara M
J Glaucoma; 2016 Mar; 25(3):e204-8. PubMed ID: 25642812
[TBL] [Abstract][Full Text] [Related]
24. One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study.
Tsukahara S; Enomoto N; Ishida K; Anraku A; Tomita G
J Ocul Pharmacol Ther; 2020 Sep; 36(7):512-521. PubMed ID: 32412867
[No Abstract] [Full Text] [Related]
25. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts.
Futakuchi A; Inoue T; Fujimoto T; Inoue-Mochita M; Kawai M; Tanihara H
Exp Eye Res; 2016 Aug; 149():107-115. PubMed ID: 27394186
[TBL] [Abstract][Full Text] [Related]
26. Morphological change and recovery of corneal endothelial cells after rho-associated protein kinase inhibitor eye-drop (ripasudil 0.4%) instillation.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Yoshikawa H; Sotozono C; Kinoshita S
Br J Ophthalmol; 2021 Feb; 105(2):169-173. PubMed ID: 32269062
[TBL] [Abstract][Full Text] [Related]
27. Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil.
Saito H; Kagami S; Mishima K; Mataki N; Fukushima A; Araie M
J Glaucoma; 2019 Apr; 28(4):289-293. PubMed ID: 30720574
[TBL] [Abstract][Full Text] [Related]
28. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
Inoue T; Tanihara H
Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
JAMA Ophthalmol; 2013 Oct; 131(10):1288-95. PubMed ID: 23787820
[TBL] [Abstract][Full Text] [Related]
30. Hyperemia Analysis Software for Assessment of Conjunctival Hyperemia Severity.
Yoneda T; Sumi T; Hoshikawa Y; Kobayashi M; Fukushima A
Curr Eye Res; 2019 Apr; 44(4):376-380. PubMed ID: 30512976
[TBL] [Abstract][Full Text] [Related]
31. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma.
Pakravan M; Beni AN; Ghahari E; Varshochian R; Yazdani S; Esfandiari H; Ahmadieh H
Am J Ther; 2017; 24(6):e676-e680. PubMed ID: 26825486
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
[TBL] [Abstract][Full Text] [Related]
33. Interaction Between Pilocarpine and Ripasudil on Intraocular Pressure, Pupil Diameter, and the Aqueous-Outflow Pathway.
Yamagishi-Kimura R; Honjo M; Komizo T; Ono T; Yagi A; Lee J; Miyata K; Fujimoto T; Inoue T; Tanihara H; Nishida J; Uchida T; Araki Y; Aihara M
Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1844-1854. PubMed ID: 29677344
[TBL] [Abstract][Full Text] [Related]
34. Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells.
Okumura N; Okazaki Y; Inoue R; Nakano S; Fullwood NJ; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7560-7. PubMed ID: 26618648
[TBL] [Abstract][Full Text] [Related]
35. Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical Study.
Nakagawa H; Koizumi N; Okumura N; Suganami H; Kinoshita S
PLoS One; 2015; 10(9):e0136802. PubMed ID: 26367375
[TBL] [Abstract][Full Text] [Related]
36. Role of ripasudil as an adjunct treatment in the management of pseudoexfoliative glaucoma.
Mohapatra S; Thakur S; Panda BB; Das P
Indian J Ophthalmol; 2023 Jul; 71(7):2756-2759. PubMed ID: 37417116
[TBL] [Abstract][Full Text] [Related]
37. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
Honjo M; Tanihara H
Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
[TBL] [Abstract][Full Text] [Related]
38. Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing.
Okumura N; Okazaki Y; Inoue R; Kakutani K; Nakano S; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1284-92. PubMed ID: 26998714
[TBL] [Abstract][Full Text] [Related]
39. Effect of ripasudil on diabetic macular edema.
Minami Y; Song YS; Ishibazawa A; Omae T; Ro-Mase T; Ishiko S; Yoshida A
Sci Rep; 2019 Mar; 9(1):3703. PubMed ID: 30842496
[TBL] [Abstract][Full Text] [Related]
40. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
Curr Eye Res; 2014 Aug; 39(8):813-22. PubMed ID: 24502505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
